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Orexin/hypocretin peptide mutations are rare in humans. Even though human narcolepsy
is associated with orexin deficiency, this is only extremely rarely due to mutations in the
gene coding prepro-orexin, the precursor for both orexin peptides. In contrast, coding and
non-coding variants of the OX1 and OX2 orexin receptors have been identified in many
human populations; sometimes, these have been associated with disease phenotype,
although most confer a relatively low risk. In most cases, these studies have been based
on a candidate gene hypothesis that predicts the involvement of orexins in the relevant
pathophysiological processes. In the current review, the known human OX1/HCRTR1
and OX2/HCRTR2 genetic variants/polymorphisms as well as studies concerning their
involvement in disorders such as narcolepsy, excessive daytime sleepiness, cluster
headache, polydipsia-hyponatremia in schizophrenia, and affective disorders are discussed.
In most cases, the functional cellular or pharmacological correlates of orexin variants
have not been investigated—with the exception of the possible impact of an amino
acid 10 Pro/Ser variant of OX2 on orexin potency—leaving conclusions on the nature
of the receptor variant effects speculative. Nevertheless, we present perspectives that
could shape the basis for further studies. The pharmacology and other properties of the
orexin receptor variants are discussed in the context of GPCR signaling. Since orexinergic
therapeutics are emerging, the impact of receptor variants on the affinity or potency of
ligands deserves consideration. This perspective (pharmacogenetics) is also discussed in
the review.
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INTRODUCTION
The orexin/hypocretin system was identified by two groups.
de Lecea with colleagues described two putative peptide trans-
mitters, encoded by a propeptide, the gene for which is
located at human chromosome 17q21.2 (de Lecea et al.,
1998). The hypocretin peptides were named for their expres-
sion in the synaptic vesicles in the hypothalamus and for
the homology of hypocretin-2/orexin-B with some incretin
peptides. The hypocretin-2/orexin-B peptide was shown to
be markedly neuroexcitatory in neuronal cultures (de Lecea
et al., 1998). Contemporaneously, Sakurai and co-workers deor-
phanized the putative G protein-coupled receptor (GPCR),
HFGAN72, and identified the two peptide transmitters that
activated the receptor, the common precursor peptide and
its gene and, finally, a second receptor based on a sequence
homology search (Sakurai et al., 1998). Peptide–receptor phar-
macology was established and mRNA expression and pep-
tide distribution in the central nervous system (CNS) was
mapped.
Orexin-A/hypocretin-1 and orexin-B/hypocretin-2 are 33-
and 28-residue hypothalamic peptides, respectively, derived from
a 130 (or 131, depending on species)-amino acid precursor,
prepro-orexin (PPO). The peptides were found to be linked to the
regulation of feeding behavior based on evidence that they stim-
ulated food intake upon intracerebroventricular administration,
and increased peptide mRNA expression in the hypothalamus
upon fasting. Sakurai et al. termed the peptides orexins for their
orexinergic function, and the receptors OX1 and OX2 receptors
(Sakurai et al., 1998).
Subsequently, genetic and disease-based studies supplied
major findings concerning the physiological role of orexins in
the regulation of wakefulness and sleep pattern. Mignot and co-
workers isolated two OX2 receptor gene frame-shift mutations
responsible for hereditary canine narcolepsy (Lin et al., 1999).
The frame shifts generate a premature in-frame stop codon, and
the truncated receptors remain cytosolic and do not traffic at all
to the plasma membrane (Hungs et al., 2001). Simultaneously,
Yanagisawa and co-workers showed that knockout of the precur-
sor peptide, PPO, causes narcoleptic phenotype inmice (Chemelli
et al., 1999). In 2000, a report found orexin-A to be at very low
or undetectable levels in the cerebrospinal fluid (CSF) of human
narcoleptics with cataplexy (Nishino et al., 2000). In contrast,
mutations in PPO gene have been identified in only a few patients
(Peyron et al., 2000; Gencik et al., 2001).
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Further studies have established that the neurobiology of the
orexin system is complex, having possible roles in stress responses,
reward/addiction, analgesia, in addition to sleep and wakeful-
ness and appetite/metabolism (Kukkonen, 2013). In the CNS,
the complexity is primarily created by the wide range of orexin
neuron projections. On the cellular level, orexin receptor activa-
tion produces highly diverse cellular signals. This is likely a result
of orexin receptor coupling to several families of heterotrimeric
G proteins and other proteins that ultimately regulate entities
such as ion channels, phospholipases and protein kinases, which
impact on neuronal excitation, synaptic plasticity, and cell death,
tomention a few (Kukkonen, 2013; Kukkonen and Leonard, 2014;
Leonard and Kukkonen, 2014). The selection of signal cascade in
each case is likely determined by the expression profile of signal-
ing components, signal complexes and other concurrent signals.
The possibly distinct role of the two orexin peptides and two
orexin receptors is not resolved.
Gene variants for the orexin peptides and, especially, their
G protein-coupled receptors, OX1 and OX2, have been iden-
tified (Figures 1, 2), and investigated in many CNS disorders,
including sleep and wakefulness (Lin et al., 1999), polydip-
sia in schizophrenia (Meerabux et al., 2005; Fukunaka et al.,
2007), panic disorder (Annerbrink et al., 2011), mood disor-
ders (Rainero et al., 2011a), migraine (Schürks et al., 2007b;
Rainero et al., 2011b), and cluster headache (Rainero et al., 2004).
The associations under investigation will ultimately benefit from
the clarification, possible from genome-wide association studies
(GWAS).
In the current report, we review the known gene variants of
orexin receptors. The major focus is on the investigations of asso-
ciation of the variants with disease phenotypes. Before presenting
those data, we present the theoretical basis of the impact of DNA
and amino acid sequence variations on the protein (here orexin
receptor) expression, structure, function and regulation. In gen-
eral, however, definitive evidence for the functional significance
of orexin receptor variants is lacking.
HOW CAN GENETIC VARIATION AFFECT PEPTIDE
TRANSMITTERS AND THEIR RECEPTORS?
Gene sequence variation for a peptide transmitter may cause
alterations in signaling at several stages. The first level could be the
gene structural level, i.e., sequence effect on the chromatin struc-
ture with impact on the transcriptional activity. mRNA stability
and processing is affected by its secondary structure. Translation
may proceed at different pace depending on the codon usage. For
correct translation, packing and proteolytic processing, the sig-
nal sequence is of great importance. Finally, the sequence may
affect the structure and the breakdown process of the transmit-
ter. For receptors, although mRNA issues are similar, there are
specific alterations in the potentially very vulnerable processes
of protein processing (folding, glycosylation), trafficking (includ-
ing wrong subcellular localization), dimerization, ligand binding,
signaling, and desensitization and down-regulation. A significant
bottle-neck of the production lies in the folding and process-
ing; some other issues, such as codon usage, may be of minor
importance.
Since there is limited knowledge of the processing of orexin
peptides and receptors, and few studies that evaluate orexin recep-
tor variants in an expression system, it is difficult to predict a role
for most of these processes for the orexin peptides or receptors.
One notable exception is the Leu16Arg mutant of the signal pep-
tide of human PPO, which impairs its processing (Peyron et al.,
2000). The best characterized orexin receptor mutants are the
three OX2 mutants found in narcoleptic canines: the two most
extreme ones cause truncation and subsequent gross protein fold-
ing failure, while the Glu54Lys variant is associated with proper
membrane localization but shows a notable loss of ligand bind-
ing and dramatically diminished calcium signaling (Hungs et al.,
2001). While these mutations (recessively) produce a strong nar-
coleptic phenotype in affected animals, the human receptor vari-
ants seem to confer significantly milder phenotypes (see below).
IMPACT OF THE GENETIC VARIATION ON THE OREXIN RECEPTOR
LIGAND BINDING
The most dramatic GPCR mutations—if we disregard the grossly
disruptive mutations such as truncations—may result in (a)
altered sensitivity to native ligands or drugs (e.g., variants of
follicle-stimulating hormone receptor causing ovarian dysgenesis;
Thompson et al., 2008b) or (b) disruption to the receptor’s inter-
action with the signal transduction machinery (e.g., G protein-
binding site mutations found in the β1-adrenoceptor; Thompson
et al., 2008c). GPCRs share a common three dimensional struc-
ture composed of seven transmembrane helices (TMs). Like other
family A GPCRs, orexin receptors are assumed to bind their pep-
tide and non-peptide ligands mainly in a partially hydrophilic,
partially hydrophobic cleft with possible contribution from more
extracellular portion of the receptor. While orexin receptor crys-
tal structures have not been published, mutagenesis studies have
been performed and receptor models constructed (Malherbe
et al., 2010; Putula et al., 2011; Tran et al., 2011; Heifetz et al.,
2012; Putula and Kukkonen, 2012). Out of the 11 variable sites
found and described in this review, only three—OX1167 [trans-
membrane helix (TM) 4, closer to intracellular side of receptor],
OX2193 (TM) 4, near the putative binding cavity and OX2308
(TM6, closer to intracellular side) (Figures 1, 2)—are within
the predicted transmembrane helix domain forming this cavity.
Among these sites, only OX2193 is located in the putative binding
cleft, where it might have a direct effect on receptor pharma-
cology. The other two sites are less likely to act through direct
molecular contacts since they are located toward the intracellular
ends of TM regions. Unfortunately, the impact of these poly-
morphisms has not been determined in heterologous expression
studies, and neither have these sites been targeted in the point-
mutation studies (Malherbe et al., 2010; Tran et al., 2011; Heifetz
et al., 2012).
Most GPCR polymorphisms are found in the loops and in
the N- and C-terminal. This is consistent with general observa-
tion that loops connecting helices are much more variable—and
in some case hypervariable—in comparison to the transmem-
brane core of GPCRs (Madsen et al., 2002; Jaakola et al., 2005),
and does not as such necessarily imply a functional signifi-
cance. However, amino acids located outside the (predicted)
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FIGURE 1 | Known amino acid sequence-changing variants of human
OX1 receptor. The variants are OX1167 Gly/Ser, OX1265 Leu/Met, OX1279
Arg/Glu, OX1280 Gly/Ala, OX1281 Arg/His, OX1408 Ile/Val, OX210 Pro/Ser, OX211
Pro/Thr, OX2193 Cys/Ser, OX2293 Ile/Val, OX2308 Val/Ile, and OX2401 Thr/Ile. The
findings originate from Peyron et al. (2000) and Olafsdottir et al. (2001). The
figure is modified from Kukkonen, J. P. (2013). Physiology of the orexinergic/
hypocretinergic system: a revisit in 2012. Am. J. Physiol. Cell. Physiol. 301,
C2–C32, © 2013. The American Physiological Society (Kukkonen, 2013).
binding cavity may also have consequences on the binding
affinities measured in pharmacological assays, as exemplified by
the canine OX2 Glu54Lys mutation (see above) (Hungs et al.,
2001). Polymorphism at the N-terminal of OX2 (Pro10Ser and
Pro11Thr; Figures 1, 2) may, similarly, act directly on ligand
binding or indirectly via receptor structure. However, also other
effects are possible, as discussed below.
Orexin-B was 2.7-fold less potent as an activator of the
OX210 Ser receptor by comparison with the wild-type OX210
Pro receptor in calcium measurements in recombinant COS-7
cells (Thompson et al., 2004). However, this may also relate to
the signaling or receptor expression/maturation; as a result, no
firm conclusions can be drawn as yet, although the finding is
interesting.
IMPACT OF THE GENETIC VARIATION ON OREXIN RECEPTOR
SIGNALING
Orexin receptors are able to couple to multiple G proteins.
Experimental evidence suggests that OX2 receptors in human
adrenal cortex activate Gi, Gs, and Gq proteins (Karteris et al.,
2001; Randeva et al., 2001). Mixed orexin receptor populations
in rat adrenal cortex or hypothalamus couple to Gi, Go, Gs, and
Gq (Karteris et al., 2005). In recombinant systems, OX1 receptors
easily couple to all these three G protein families (Holmqvist et al.,
2005; Magga et al., 2006). In summary, both orexin receptors
are likely capable of coupling to Gi/o, Gs, and Gq family G pro-
teins; however, this may be subject to tissue- and context-specific
regulation (Kukkonen, 2013). For G protein coupling, the most
central receptor domains are usually the 2nd and 3rd intracellular
loops, while also the 1st intracellular loop and the receptor’s C-
terminus are sometimes implicated based on mutagenesis studies
(Wess, 1998); orexin receptors themselves have not been exam-
ined for this. Like other GPCRs (Ritter and Hall, 2009), orexin
receptors may also couple to other proteins, like β-arrestin and
dynein light chain Tctex-type 1 (Milasta et al., 2005; Dalrymple
et al., 2011; Duguay et al., 2011). Coupling to both these proteins
is suggested to take place on the receptor’s C-terminus. Variations
in these regions may directly impact orexin receptor interaction
with effectors while also indirectly modifying effector coupling
as a result of alterations in the receptor configuration that deter-
mines the specificity of these interactions. Among the identified
variable sites, OX1265, OX1279, OX1280, OX1281, OX1408, OX2293,
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FIGURE 2 | Known amino acid sequence-changing variants of human
OX2 receptor. The variants are OX210 Pro/Ser, OX211 Pro/Thr, OX2193
Cys/Ser, OX2293 Ile/Val, OX2308 Val/Ile, and OX2401 Thr/Ile. The findings
originate from Peyron et al. (2000) and Olafsdottir et al. (2001).
The figure is modified from Kukkonen, J. P. (2013). Physiology of the
orexinergic/hypocretinergic system: a revisit in 2012. Am. J. Physiol.
Cell. Physiol. 301, C2–C32, © 2013. The American Physiological Society
(Kukkonen, 2013).
and OX2401 (Figures 1, 2) may thus be implicated in G protein
and/or other protein coupling of orexin receptors.
Further complexity in the trafficking, ligand interaction and
signaling of GPCR is introduced by the fact that many GPCRs
have been shown to dimerize (Bulenger et al., 2005; Milligan,
2009). In fact, some models predict that all functional GPCRs
form dimers. Orexin receptors are known to homo- and hetero-
dimerize/oligomerize in recombinant expression systems (Ellis
et al., 2006; Ward et al., 2011; Xu et al., 2011; Jäntti et al., 2014).
It should be noted, however, that there is no evidence for such
interactions in native cells thus far.
GPCRs may utilize both extracellular and intracellular parts
as well as the hydrophobic outer surfaces of the transmem-
brane helices for interaction during dimerization (see, e.g., Liang
et al., 2003; Wu et al., 2010; Huang et al., 2013). One region
involved in receptor–receptor interaction, at least according to X-
ray crystal structure-based modeling of the CXCR4 (Wu et al.,
2010) and the β1-adrenoceptor (Huang et al., 2013), is near
the palmitoylated C-terminal region. An analogous structure is
present in the human orexin receptors. It may form a coiled coil
motif in the putative helix 8 (parallel to membrane) that would
allow OX1 and OX2 dimerization. The impact of OX1408 and
OX2401 (Figures 1, 2) on receptor dimerization is unknown; in
any case, they are well downstream from the potential palmitoy-
lation sites. The importance of dimerization/oligomerization for
most GPCRs, however, is unclear (Bulenger et al., 2005; Milligan,
2009). Notable exceptions to this among GPCR family A recep-
tors are the opioid receptors, whose pharmacology and trafficking
is significantly affected by dimerization. OX1–CB1 dimerization
was suggested to strongly potentiate orexin receptor signaling, but
a likely explanation for the signal potentiation is, instead, offered
by the ability of OX1 receptor signaling to produce 2-arachidonoyl
glycerol, a CB1 receptor ligand, and a subsequent co-signaling
of the receptors (Haj-Dahmane and Shen, 2005; Turunen et al.,
2012; Jäntti et al., 2013). However, this does not preclude
dimerization.
Phosphorylation (or other similar protein interaction) dif-
ferences may be seen between the variants. Hydroxyl group-
containing amino acids Ser, Thr and Tyr may be direct substrates
for phosphorylation, but other amino acids can also affect the
kinase consensus sequences. These sites have not been targeted
in the point mutagenesis studies. Scansite (http://scansite.mit.
edu/) (Obenauer et al., 2003) motif search suggest that some of
the polymorphisms at OX1167, OX1265, OX1279, OX1280, OX1408,
and OX2401 (Figures 1, 2) may impact kinase or other protein
binding. Because these predictions are solely based on the amino
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acid sequence, however, they should be treated with caution.
It is also unclear whether all these sites, especially OX1167, are
accessible for interaction.
IMPACT OF GENETIC VARIATION ON THE OREXIN PEPTIDE AND
RECEPTOR PROCESSING, FOLDING AND HALF-LIFE
It is very difficult to predict the sites affecting receptor fold-
ing; in principle, every residue can influence receptor folding on
the local or a more general level. A major change in the amino
acid size, conformation, polarity and, especially, charge is likely
to have a more pronounced effect of this type. Such an impact
could be most pronounced for OX1279 Arg/Glu. Glycosylation,
found on the extracellular GPCR surfaces, could be affected by
the availability of Asn and Ser/Thr residues (and other sites in
the putative consensus sequence). This could be relevant for
the OX210 Pro/Ser, OX211 Pro/Thr, and OX2193 Cys/Ser variants
(Figures 1, 2).
Posttranslational modifications are also necessary for the pep-
tides for proper ligand function. For orexins, these include
cyclization of N-terminal Glu and correct formation of the two
disulphide bridges in orexin-A, and amidation of the free C-
terminus of both peptides (Sakurai et al., 1998). With the very
limited knowledge of the processing of orexin peptides and recep-
tors as well as the very few studies which evaluate the orexin
receptor variants in heterologous expression systems, it is diffi-
cult to predict a role for most of these processes in human disease.
The one notable exception is the Leu16Arg mutant of the signal
peptide of PPO, which impairs the processing of the PPO (Peyron
et al., 2000), stressing the importance of the signal sequence for
correct translation, packing and proteolytic processing.
For both receptors and peptides, the amino acid sequence may
impact the trafficking and half-life. Receptor internalization from
the plasma membrane is involved both in signaling and degra-
dation, and requires interaction with other proteins (see above).
Therefore, mutations may, for instance, decrease or increase the
half-life of the receptor protein or redirect signal cascades.
OREXIN PHARMACOGENETICS
Coding and non-coding variants of the OX1 and OX2 orexin
receptors have been identified in many human populations and
phenotypes. Due to the emerging market for drugs targeting OX1
and OX2 receptors, knowledge of genetic variation in the human
genes coding for these receptors, HCRTR1 and HCRTR2, respec-
tively, is of pharmacogenetic interest. Although canine HCRTR2
mutations are associated with narcolepsy (Lin et al., 1999; Hungs
et al., 2001), mutations in human orexin receptor genes have been
associated only with rather moderately elevated disease risks—
and, in some cases, the associations have not been met with
consensus. Table 1 presents a selection of the studies of OX1 and
OX2 orexin receptor variants examined in human disease states.
With respect to drug development, the orexin receptor vari-
ants may be particularly relevant. Dual orexin antagonists, such
as almorexant and suvorexant (Figure 3), as well as OX2-selective
antagonists, have been developed for use as sleep aids. Orexin
receptor antagonists seem to act to turn off wakefulness instead
of inducing sleep, per se (Winrow et al., 2011). While the devel-
opment of almorexant by Actelion Pharmaceuticals has been
curtailed, Merck and Co. has continued the development of
suvorexant (MK-4305) (Cox et al., 2010; Mieda and Sakurai,
2013; Winrow and Renger, 2014). Suvorexant completed three
Phase III trials in 2013 (Winrow and Renger, 2014). TheU.S. Food
and Drug Administration’s (FDA) peripheral and CNS advisory
committee found the drug generally safe and effective for treat-
ing sleep maintenance and latency. Although it has a promising
side-effect profile, the FDA review suggested that suvorexant is
associated with increased somnolence the day after use, and that
higher doses may be associated with an increased rate of suicidal
ideation (Mieda and Sakurai, 2013). Pharmacogenetic consider-
ations may assist in establishing the correct dosing for patients.
Conversely, orexin receptor-activating therapy may become avail-
able for narcolepsy. Some recent findings support this therapeutic
concept (Liu et al., 2011; Kantor et al., 2013). Narcolepsy may,
however, not be the only disorder where such therapymay be ben-
eficial, as indicated by some results briefly presented below and in
Kukkonen (2012) and Kukkonen (2013).
Given the frequency of OX1 and OX2 receptor amino acid
sequence variants, there is a clear rationale for examining the
pharmacology of the agents at the variants in vitro. These results
may, in turn, justify studying drug response in patients carrying
receptor variants. For many human GPCRs, amino acid vari-
ants are well known to confer distinct pharmacological properties
(Thompson et al., 2005, 2008a); however, the pharmacologi-
cal data is generally unavailable for the human orexin receptor
variants (Kukkonen, 2013).
OREXIN RECEPTOR VARIANTS IDENTIFIED IN
SLEEP/WAKEFULNESS DISORDERS
Genetic variants of the orexin system have been identified only
rarely in narcolepsy. For example, the Leu16Arg mutation in the
signal peptide of PPO (Peyron et al., 2000; Gencik et al., 2001) dis-
rupts a region of neutral, hydrophobic polyleucine amino acids
in the PPO, which, in turn, limits the biologically active prod-
ucts, orexin-A and -B (Peyron et al., 2000). In contrast, the DNA
or amino acid sequence variants of human HCRTR1/OX1 and
HCRTR2/OX2 receptors (Figures 1, 2) do not seem to be involved
in narcolepsy (Peyron et al., 2000; Olafsdottir et al., 2001)
OX211 Thr variant was identified in two DQB1∗0602-negative
excessive daytime sleepiness (EDS) patients and an OX210 Ser
variant in a Tourette’s syndrome patient comorbid with atten-
tion deficit hyperactivity disorder (ADHD) (Thompson et al.,
2004). OX210 Ser or OX211 Thr variants were not identified in the
110 control individuals assessed, suggesting a possible association
with sleep disorders. The fact that Tourette’s syndrome patients
diagnosed comorbid with ADHD frequently experience sleep dis-
orders (Allen et al., 1992; Freeman et al., 2000; Cohrs et al., 2001),
suggest that the OX210 Ser might be involved in the aetiology of
some sleep abnormalities. Furthermore, while the OX210 Ser and
OX211 Thr variants were reported to be more common in HLA
DQB1∗0602-negative narcoleptics compared with controls, these
variants were reported to be benign with respect to narcolepsy
(Peyron et al., 2000). The presence of these variants in EDS and
Tourette’s syndrome patients, however, suggests that they should
be evaluated in vitro for functional differences that may con-
tribute to sleep dysregulation. In this context, it is interesting to
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FIGURE 3 | Structures of some orexin receptor antagonists developed
for insomnia. Structures are rendered using ChemBioDraw Ultra 13.0
(PerkinElmer, Waltham, MA, USA).
note that orexin-A/orexin-B pharmacology was suggested to be
altered in OX210 Ser as compared to the wild-type OX210 Pro vari-
ant (see Impact of the genetic variation on the orexin receptor
ligand binding).
Thus, orexin receptor sequence variation may contribute to
sleep disorders (OX211 Thr, possibly OX210 Ser). This is by no
means surprising; it may rather be unexpected that so few find-
ings of this type have been described. However, dramatic orexin
receptor mutations might have such a detrimental effect on the
regulation of wakefulness that they have been eliminated from the
population, while milder phenotypes persist.
THE ROLE OF THE OREXIN SYSTEM IN HEADACHES
The orexin system has been examined in various forms of
headache including migraine and cluster headache. While cluster
headache is a rare, extremely debilitating headache that occurs
in groups (or clusters) during seasonal changes (Goadsby,
2002), migraines are comparatively common headaches that
are comparatively more treatable with non-steroid anti-
inflammatory drugs or specific serotonergic drugs. Migraines
often run in families where as cluster headaches are more sporadic
(Benoliel and Eliav, 2013). While genome-wide studies have
resulted in better understanding of migraine (Thompson et al.,
2012), many complex traits, including cluster headache, have
been less amenable to study—possibly due to their heterogeneity
(Rainero et al., 2011b).
Cluster headache consists of attacks of sudden, severe, uni-
lateral periorbital pain, accompanied by restlessness and cranial
autonomic symptoms, and is characterized by a strikingly unique
circadian and circannual rhythmicity (Goadsby, 2002). There is
increasing evidence that cluster headache may have a significant
genetic component. Genetic epidemiological studies have sug-
gested that first-degree relatives of cluster headache probands are
more likely to have cluster headache than the general popula-
tion (Russell et al., 1996; Leone et al., 2001; El Amrani et al.,
2002). Cluster headache has been found to be an autosomal
dominant trait in some affected families, but despite numerous
attempts, no clear molecular genetic basis has been identified
for cluster headache (Russell, 2004). Segregation analysis suggests
that cluster headache is a complex disease: several genetic factors
may result in cluster headache when the correct environmental
conditions are present (Pinessi et al., 2005).
Since there is no major gene effect for the orexin loci linked to
migraine, the orexins have tended to be studied more frequently
in cluster headache, where a model of complex genetic traits
suggests multifactorial involvement that may include orexin loci.
Numerous common polymorphisms of HCRTR1 and HCRTR2
have been studied in cluster headache (below), though the fre-
quency and physiological significance of these variants is still
being investigated (Rainero et al., 2004; Schürks et al., 2007a;
Rainero et al., 2011b).
A number of studies provide evidence that orexins are involved
in pain modulation within brain structures in the midbrain,
indicating a possible link between orexins and the nociceptive
phenomena observed in primary headache disorders (Bingham
et al., 2001; Kajiyama et al., 2005;Mobarakeh et al., 2005). Orexin-
producing neurons of CNS are also specifically located to the
postero- and dorsolateral hypothalamus, regions implicated in
cluster headache (May et al., 1998, 1999). The role of orexins in
noradrenergic activation, shown by innervation and stimulation
of the locus coeruleus in rats, monkeys and cats (Hagan et al.,
1999; Horvath et al., 1999; Diano et al., 2003), may implicate
changes in blood flow in cluster headache, although this evi-
dence is not conclusive (Cohen and Goadsby, 2004). This suggests
complexity of the cluster headache etiology.
OX1 RECEPTORS IN MIGRAINE
In addition to synonymous SNPs (rs10914456, rs4949449), a
non-synonymous HCRTR1 polymorphism of G1222A in exon 7
(rs2271933) encoding an OX1 Ile408Val substitution, has been
implicated in migraine. Genotype and allele frequencies of the
rs2271933 non-synonymous polymorphism have been associated
with a 1.4-fold risk of migraine (Rainero et al., 2011b). The
functional significance of this common OX1 receptor variant
is not fully understood, however. While OX1408 in the recep-
tor’s C-terminus resides is likely to be located within the
region for interaction with other proteins (below), it has not
been experimentally resolved whether the mutation changes the
receptor’s expression level, coupling to effectors, or homo- or
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heterodimerization. Neither OX1408 variant correlates with
human narcolepsy (Peyron et al., 2000; Olafsdottir et al., 2001).
OX2 RECEPTORS IN CLUSTER HEADACHE
While the literature on the OX2/HCRTR2 polymorphisms
(rs1049880, rs3122156T, rs9357855G, rs2653342A, rs2653349G)
is large, it remains inconclusive (Rainero et al., 2004, 2008). In
particular, homozygosity for the common G allele of rs2653349
(1246 G/A), encoding OX2308 Val, has been associated with an
increased disease risk for cluster headache—as compared to the
OX2308 Ile variant—in some, but not all studies. The associa-
tion was confirmed in a large study fromGermany—showing that
homozygous carriers of the G allele had a 2-fold increase in cluster
headache risk (Schürks et al., 2006)—but not in a GWAS study of
cluster headache patients of Danish, Swedish, and British origin
(Baumber et al., 2006).
Additionally five intronic polymorphisms, covering more than
75% of the entire 108.35 kb sequence of the HCRTR2 gene, were
used to evaluate the association between cluster headache and
the OX2/HCRTR2 (Rainero et al., 2008). A significant difference
between cluster headache cases and controls was found for 3 out
of the 5 examined polymorphisms. Carriage of the GTAAGG
haplotype—defined as a combination of the intronic positions
Rs2653349, Rs3122156, Rs9357855, Rs2653342 and Rs3800539,
and the exonic Rs2653349 (above)—was shown to be associ-
ated with cluster headache, resulting in a 3.7-fold increased risk.
Sequence analysis of genomic DNA for the entire coding region
of the OX2/HCRTR2 gene in 11 cluster headache patients, identi-
fied no additional coding sequence difference besides rs2653349.
The functional relevance of these intronic variants and how they
impact cluster headache, remains to be determined (Rainero
et al., 2008). In another study, neither one of the rs2653349 alleles
(OX2308 Val or Ile) was associated with response to drugs, such as
triptans, in cluster headache (Schürks et al., 2007a).
In conclusion, orexin receptor variants OX1408 Val and OX2308
Val have been associated with a somewhat elevated risk for
migraine and cluster headache, respectively. While the intra-
cellular OX1408 may affect the receptor interaction with other
intracellular or plasma membrane proteins, and the TM6 OX2308
ligand binding, it is not known whether variants at these amino
acids result in distinct functional properties, or if the difference
might be found in differential processing etc., as suggested by
co-segregation of OX2308 Val with the intronic HCRTR2 poly-
morphisms. Future studies should address the significance of
co-inheritance of variants of both receptors.
OREXIN RECEPTOR VARIANTS IN PSYCHIATRIC DISORDERS
ANXIETY DISORDERS
The role of the orexins in anxiety disorders is currently unclear
because orexins have been suggested to be both anxiogenic
and anxiolytic—or possibly even neutral—in investigations in
rodent models (Kukkonen, 2013). Nevertheless, orexinergic
interventions into panic disorder are currently under investiga-
tion (Perna et al., 2011). Panic disorder is an anxiety disorder
characterized by unexpected attacks of fear with enhanced arousal
and somatic symptoms (Meuret et al., 2011). The heritability
of panic disorder has been estimated to be 50% (Hettema
et al., 2001); however, the inheritance is most likely multifacto-
rial. The rational for examining the involvement of orexins in
panic disorder also reflects indications of orexin-mediated reg-
ulation of respiration (Kuwaki, 2008; Williams and Burdakov,
2008)—dysregulation of respiration is a hallmark of panic attacks.
Orexin neurons innervate brain nuclei, such as the reticular for-
mation of the medulla, that control respiration (Peyron et al.,
1998). PPO knockout mice exhibit a decreased response to CO2
that is partly restored by supplementation with orexin (Deng
et al., 2007). OX1 receptor antagonist, SB-334867, mimics the
PPO knockout phenotype when administered to wild-type mice.
Intracerebroventricular administration of orexin promotes respi-
ration in rodents (Zhang et al., 2005; Johnson et al., 2012); in rats,
this has been shown to be blocked by SB-334867 (Johnson et al.,
2012).
OX2308 Ile variant has been associated with panic disorder
in female patients (Annerbrink et al., 2011). In contrast, nei-
ther male nor female populations showed a risk associated with
either variant (Val or Ile) of OX1408 (Annerbrink et al., 2011).
Functional analysis of variant orexin receptors may provide
insight into these allele associations.
MOOD DISORDERS
Studies in rodents have suggested that orexins may also be
involved in the pathogenesis of mood disorders. Wistar-Kyoto
rats, an animal model of depression, have a reduced number of
hypothalamic cells expressing orexin immunoreactivity (Allard
et al., 2007). Furthermore, neonatal administration of the tricyclic
antidepressant clomipramine may result in decreased orexin con-
centrations in brain regions such as the hypothalamus (Feng et al.,
2008).
Consistent with this, intracerebroventricular administration
of orexin-A has a long-term antidepressessive effect in some
rodent depression paradigms; an effect that may involve hip-
pocampal neurogenesis (Ito et al., 2008). Activation of orexin-
ergic neurons leads to the excitation of major monoaminergic
nuclei of the brain stem, including raphe nuclei (serotonin),
locus coeruleus (norepinephrine), and the ventral tegmental area
(dopamine) (Peyron et al., 1998; Leonard and Kukkonen, 2014).
Furthermore, orexin knockout mice show a significant reduction
in the dopamine turnover rate and a compensatory increase of
serotoninergic activity possibly suggesting a relationship between
monoamines and orexins (Mori et al., 2010).
The role of orexins in drug addiction and reward (Aston-
Jones et al., 2010; Boutrel et al., 2010; Thompson and Borgland,
2011) may be linked to the proposed involvement of orexins
in mood regulation, and the tendency of depressed patients to
self-medication. The few studies conducted in humans suggest
decreases in CSF orexin-A concentrations or its rhythmicity in
depression (Salomon et al., 2003; Brundin et al., 2007).
The possible contribution of orexin receptor variants to axis
I disorders, however, has not been widely studied. For example,
the functional OX211 Ser variant identified in Tourette’s syndrome
has not been examined in other patient cohorts. By comparison,
studies of the OX1408 Val variant have reported it to be asso-
ciated with a 1.6-fold increased risk of major mood disorders
as compared to the OX1408 Ile (Rainero et al., 2011a). Patients
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homozygous for the Val-coding allele (1222A; rs2271933)—in
comparison with those homozygous for the Ile-coding allele
(1222G)—have an even higher, 2.5-fold increased risk for mood
disorders, as also confirmed by haplotype analysis (Rainero et al.,
2011a). Functional analysis of variant orexin receptors may con-
firm the relevance of these findings.
SCHIZOPHRENIA
OX1408 Ile/Val polymorphism has been studied in schizophrenia
patients. Specifically, variation was associated with polydipsia–
hyponatremia in schizophrenic patients when compared with
non-polydipsic patients (Meerabux et al., 2005; Fukunaka et al.,
2007); however, the associations were found for the opposite
variants in the two studies.
Orexin regulation of water intake has been suggested by
the anatomy of orexinergic projections to, for instance, sub-
fornical organ and area postrema (Kukkonen et al., 2002).
Intracerebroventricular infusion of orexin-A, more potently, but
also of orexin-B, acutely increases water intake and drinking in
rats (Kunii et al., 1999; Rodgers et al., 2000; Takano et al., 2004;
Zheng et al., 2005; Kis et al., 2012), while in the continuous treat-
ment (7 or 14 days), the effect wanes (Lin et al., 2002). PPO
mRNA expression in the hypothalamus is upregulated uponwater
deprivation (Kunii et al., 1999). Orexin-A also excites subforni-
cal organ neurons (Ono et al., 2008). Orexin-A alone does not
affect baseline vasopressin release, but inhibits histamine-induced
release in OX1 receptor-dependent manner (Russell et al., 2001;
Kis et al., 2012). In golden hamster, infusion of orexin-B, but not
orexin-A, in the amygdala stimulates water intake (Avolio et al.,
2012).
Thus, one physiological role of orexins may be in the regula-
tion of water intake. Whether this has a role in schizophrenia-
associated polydipsia, remains to be shown. However, the
dopamine D2-type receptor agonist, quinpirole, increases water
intake, which is further enhanced by blocking OX1 receptors with
SB-334867 (Milella et al., 2010), which would rather suggest an
opposite role for orexin signaling under these conditions.
CONCLUSIONS AND PERSPECTIVES
Human orexin receptor sequence variation has been investigated
in the context of disease-based targeted approaches, first with
narcolepsy and then with other diseases. Variants have been iden-
tified, some with an apparent relevance for the disease(s) under
investigation, some not. Interestingly, the same variants that are
putatively associated with headaches, namely OX1408 and OX2308
have been implicated in panic disorder, mood disorders and in
polydipsia in schizophrenia. The “overrepresentation” of these
variants in many disorders, however, may be an artifact from the
candidate gene rational used to select these loci. However, in none
of the cases has a very high risk been identified. Nevertheless, we
suggest that the full functional phenotype of each receptor vari-
ant should be established; currently of greatest interest are the
OX1408, OX210, OX211, and OX2308 variants. In the absence of
these data, the reasons behind the observations are difficult to
speculate on.
So far, none of the orexin receptor variants has conferred a
very high disease risk or apparently a very grave phenotype. Is
this because the two orexin receptor subtypes are simply too
redundant; are the data sets confounded by a lack of valid dis-
ease phenotype classifications and an inadequate consideration
of contributing environmental factors; or are the phenotypes
carried by the known human orexin receptor gene variants sim-
ply rather mild? Currently, we cannot resolve this dilemma. We
might assume, however, that any genotype grossly hampering
orexin receptor function would be eliminated from the popula-
tion due to its strong impact on the wakefulness, and thus the
genotypes present only confer mild phenotypes. In essentially
all cases we have to recognize the fact that cellular phenotypes
of the orexin receptor variants have not been investigated, and
conclusions based on this are thus vague. Evidence for a signifi-
cant association of certain haplotypes of orexin genes with disease
will inevitably be re-evaluated from a genome-wide perspective
(GWAS) and with respect to the risk factors posed by other
genetic and environmental variables. Although orexin receptor
mutations may, alone, not confer highly increased risk (or protec-
tion) for a disease, these findings may propel studies concerning
the physiological roles of orexins, and therefor also identify novel
therapeutic approaches.
More complete study of orexins pharmacogenetics may facil-
itate novel areas of orexin research. This approach may help
to refine drug design by targeting variant receptors. The con-
tinued study of orexin pharmacogenetics and receptor function
at the cellular level is necessary before the role of orexinergic
ligands in the treatment of disorders such as migraine, clus-
ter headache, EDS and even idiopathic narcolepsy can be pre-
dicted fully. The emergence of dual orexin receptor antagonists,
as well the possible OX2-selective ones (Dugovic et al., 2009;
Etori et al., 2014), reinforces evidence for the partly overlapping
and partly distinct roles of orexin receptors in the regulation
of sleep/wakefulness states. Characterization of variant receptor
pharmacology may be of further use in establishing pharmaco-
genetic profiles for the drugs. Specific groups of sleep disorder
patients may benefit from these compounds. For example, the
sleep disturbances characteristic of Parkinson’s and Alzheimer’s
diseases may be amenable to orexinergic drugs. Parkinson’s dis-
ease patients frequently complain of sleep disturbances and loss
of muscle tone during rapid-eye-movement (REM) sleep. A
more complete evaluation of the pharmacology of orexin recep-
tor variants may facilitate the development of orexin receptor
agonists.
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